Drug Database
Back to search

United States· US:50090-8016_571ce280-f506-436c-b378-d570cceae236

RELENZA

A zanamivir product containing zanamivir, registered in United States by A-S Medication Solutions. The same ATC class is registered in 15 of our 19 countries.

ATC J05AH01

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedRELENZAATCJ05AH01REGISTER NO.US:50090-8016_571ce28…PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about zanamivirAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Zanamivir is registered in 15 of 19 countries.

Countries holding a registration under ATC J05AH01 (zanamivir), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 9 of them publish a price we can compare per daily dose
Search zanamivir products by name

Zanamivir · ATC J05AH01

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
ZANAMIVIR
Manufacturer
A-S Medication Solutions
Country
United States (US)
ATC code
J05AH01
ATC class
Zanamivir
Defined daily dose
20 mg, Inhal
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 27, 2026

Packs & prices · 1

  • ndc11
    50090-8016-0

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

13 interactions on record for zanamivir.

Graded by severity as the source publishes them — 5 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check zanamivir against other medicinesHow interaction checks work

Zanamivir · interactions on record

13 records

  • 5 moderate
  • 8 info

Most severe, free to view

  • Insulin (human)A10AB01moderate
  • Insulin (human)A10AC01moderate
  • Insulin (human)A10AD01moderate
  • Insulin (human)A10AE01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Zanamivir in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All zanamivir products

Authorised across Europe · EMA

The same active substance is authorised in 21 EEA countries. Names it is sold under:

  • Austria · Relenza Rotadisks
  • Belgium · Relenza
  • Bulgaria · Реленца
  • Germany · Relenza
  • Denmark · Relenza
  • Spain · Relenza
  • Finland · Relenza
  • France · Relenza
  • United Kingdom (Northern Ireland) · Relenza
  • Croatia · Relenza
  • Ireland · Relenza
  • Iceland · Dectova, Relenza
  • Italy · Relenza
  • Liechtenstein · Dectova
  • Luxembourg · Relenza
  • Netherlands · Relenza
  • Norway · Dectova, Relenza
  • Poland · Relenza
  • Portugal · Relenza
  • Sweden · Relenza
  • Slovenia · Relenza

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/db801b09-88b4-470b-9307-2f0db45a74b6
GET /v1/drugs/db801b09-88b4-470b-9307-2f0db45a74b6?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "RESPIRATORY (INHALATION)",
  "source": "ndc",
  "strength": "5",
  "substance": "ZANAMIVIR",
  "productndc": "50090-8016",
  "dosage_form": "POWDER",
  "dea_schedule": null,
  "strength_unit": "mg/1",
  "application_number": "NDA021036",
  "marketing_category": "NDA"
}
API referenceMCP serverPlans

See everything about zanamivir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console